bioRxivBioengineeringPreprint
Matrix mechanics, not hypoxia, modulate quiescin sulfhydryl oxidase 1 (QSOX1) in pancreatic tumor cells
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer-related deaths in the U.S., despite only being the 11th most common cancer. The high mortality rates of PDAC can be partially attributed to the tumor microenvironment. Unlike most carcinomas, PDAC is characterized by a strong desmoplastic reaction, or a fibrotic stiffening of the extracellular matrix (ECM) in response to chronic inflammation. The desmoplastic reaction is mediated by cancer-associated fibroblasts that deposit ECM proteins (collagens, laminins, fibronectin, etc.) and secrete matrix-remodeling proteins in the tumor parenchyma. Within the past decade, the enzyme quiescin sulfhydryl oxidase 1 (QSOX1) has gained recognition as a significant contributor to solid tumor pathogenesis, but its biological role remains uncertain. QSOX1 is a disulfide bond-generating catalyst that participates in oxidative protein folding in the mammalian cell. Current studies show that inhibiting or knocking down QSOX1 reduces pancreatic cancer cell migration and invasion, alters ECM deposition and organization, and decreases overall tumor growth in mice. However, it is unclear which features of the tumor microenvironment modulate QSOX1 and cause its overexpression in cancer. In this study, we explored potential regulators of QSOX1 expression and secretion by testing two major features of PDAC: hypoxia and mechanical stiffness. To induce hypoxia, we exposed pancreatic cancer cells to atmospheric (low O2) and chemical (CoCl2) hypoxia for up to 48 hours. QSOX1 gene and protein expression did not change in response to hypoxia. Substratum stiffness was modulated using polyacrylamide gels to represent the dynamic pathological range of elastic moduli found in PDAC tissue. We discovered that QSOX1 levels were decreased on softer surfaces compared to conventional tissue culture plastic. This paper presents new results and challenges prior findings on QSOX1 regulation in pancreatic tumor cells.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Hypoxia induces extensive protein and proteolytic remodeling of the cell surface in pancreatic adenocarcinoma (PDAC) cell lines
Irene Lui, Kaitlin Schaefer, … James A. Wells·Journal of Proteome ResearchPeer-reviewed·May 1, 2025
- Hypoxia promotes an inflammatory phenotype of fibroblasts in pancreatic cancer
- Mechanobiology-guided drug repurposing identifies budesonide as an inhibitor of stiffness-induced PDAC aggressiveness
Simone Mas, Marco Cristiano, … Cristina D’Aniello·bioRxiv·Jul 20, 2026
- NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer
J. Doffo, S. A. Bamopoulos, … M. Wirth·bioRxiv·Oct 21, 2021
- Dexamethasone Inhibits Cytokine-Induced, DUOX2-Related VEGF-A Expression and DNA damage in Human Pancreatic Cancer Cells and Growth of Pancreatic Cancer Xenografts
Y. Wu, M. M. Konate, … J. H. Doroshow·bioRxiv·Feb 13, 2022
- Engineered extracellular matrices reveal stiffness-mediated chemoresistance in patient-derived pancreatic cancer organoids
B. L. LeSavage, A. E. Gilchrist, … S. C. Heilshorn·bioRxiv·Apr 22, 2022